                               SEQUENCE LISTING



<110> ACTINIUM PHARMACEUTICALS, INC.

 

<120> METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION

      WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC



<130> ACTINIUM-5PCT



<140> PCT/US2018/029607

<141> 2018-04-26



<150> 62/491,803

<151> 2017-04-28



<160> 4     



<170> PatentIn version 3.5



<210> 1

<211> 1952

<212> DNA

<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Synthetic

      polynucleotide



<400> 1

tctagaccac catggagaaa gacacactcc tgctatgggt cctacttctc tgggttccag       60



gttccacagg tgacattcag atgacccagt ctccgagctc tctgtccgca tcagtaggag      120



acagggtcac catcacatgc agagccagcg aaagtgtcga caattatggc attagcttta      180



tgaactggtt ccaacagaaa cccgggaagg ctcctaagct tctgatttac gctgcatcca      240



accaaggctc cggggtaccc tctcgcttct caggcagtgg atctgggaca gacttcactc      300



tcaccatttc atctctgcag cctgatgact tcgcaaccta ttactgtcag caaagtaagg      360



aggttccgtg gacgttcggt caagggacca aggtggagat caaacgtaag tagaatccaa      420



agtctagaaa ttctaaactc tgagggggtc ggatgacgtg gccattcttt gcctaaagca      480



ttgagtttac tgcaaggtca gaaaagcatg caaagccctc agaatggctg caaagagctc      540



caacaaaaca atttagaact ttattaagga atagggggaa gctaggaaga aactcaaaac      600



atcaagattt taaatacgct tcttggtctc cttgctataa ttatctggga taagcatgct      660



gttttctgtc tgtccctaac atgctctgtg attatccgca aacaacacac ccaagggcag      720



aactttgtta cttaaacacc atcctgtttg cttctttcct caggaactgt ggctgcacca      780



tctgtcttca tcttcccgcc atctgatgag cagttgaaat ctggaactgc ctctgttgtg      840



tgcctgctga ataacttcta tcccagagag gccaaagtac agtggaaggt ggataacgcc      900



ctccaatcgg gtaactccca ggagagtgtc acagagcagg acagcaagga cagcacctac      960



agcctcagca gcaccctgac gctgagcaaa gcagactacg agaaacacaa agtctacgcc     1020



tgcgaagtca cccatcaggg cctgagctcg cccgtcacaa agagcttcaa caggggagag     1080



tgttagaggg agaagtgccc ccacctgctc ctcagttcca gcctgacccc ctcccatcct     1140



ttggcctctg accctttttc cacaggggac ctacccctat tgcggtcctc cagctcatct     1200



ttcacctcac ccccctcctc ctccttggct ttaattatgc taatgttgga ggagaatgaa     1260



taaataaagt gaatctttgc acctgtggtt tctctctttc ctcatttaat aattattatc     1320



tgttgtttta ccaactactc aatttctctt ataagggact aaatatgtag tcatcctaag     1380



gcgcataacc atttataaaa atcatccttc attctatttt accctatcat cctctgcaag     1440



acagtcctcc ctcaaaccca caagccttct gtcctcacag tcccctgggc catggtagga     1500



gagacttgct tccttgtttt cccctcctca gcaagccctc atagtccttt ttaagggtga     1560



caggtcttac agtcatatat cctttgattc aattccctga gaatcaacca aagcaaattt     1620



ttcaaaagaa gaaacctgct ataaagagaa tcattcattg caacatgata taaaataaca     1680



acacaataaa agcaattaaa taaacaaaca atagggaaat gtttaagttc atcatggtac     1740



ttagacttaa tggaatgtca tgccttattt acatttttaa acaggtactg agggactcct     1800



gtctgccaag ggccgtattg agtactttcc acaacctaat ttaatccaca ctatactgtg     1860



agattaaaaa cattcattaa aatgttgcaa aggttctata aagctgagag acaaatatat     1920



tctataactc agcaatccca cttctaggat cc                                   1952





<210> 2

<211> 238

<212> PRT

<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Synthetic

      polypeptide



<400> 2

Met Glu Lys Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 

1               5                   10                  15      





Gly Ser Thr Gly Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser 

            20                  25                  30          





Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ser 

        35                  40                  45              





Val Asp Asn Tyr Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro 

    50                  55                  60                  





Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Gln Gly Ser 

65                  70                  75                  80  





Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 

                85                  90                  95      





Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys 

            100                 105                 110         





Gln Gln Ser Lys Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val 

        115                 120                 125             





Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 

    130                 135                 140                 





Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu 

145                 150                 155                 160 





Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 

                165                 170                 175     





Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 

            180                 185                 190         





Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 

        195                 200                 205             





Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 

    210                 215                 220                 





Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 

225                 230                 235             





<210> 3

<211> 3246

<212> DNA

<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Synthetic

      polynucleotide



<400> 3

tctagaccac catgggatgg agctggatct ttctcttcct cctgtcagga actgctggcg       60



tccactctca ggttcagctg gtgcagtctg gagctgaggt gaagaagcct gggagctcag      120



tgaaggtttc ctgcaaagct tctggctaca ccttcactga ctacaacatg cactgggtga      180



ggcaggctcc tggccaaggc ctggaatgga ttggatatat ttatccttac aatggtggta      240



ccggctacaa ccagaagttc aagagcaagg ccacaattac agcagacgag agtactaaca      300



cagcctacat ggaactctcc agcctgaggt ctgaggacac tgcagtctat tactgcgcaa      360



gagggcgccc cgctatggac tactggggcc aagggactct ggtcactgtc tcttcaggta      420



agaatggcct ctagaccacc atgggatgga gctttctggg gcaggccagg cctgaccttg      480



gctttggggc agggaggggg ctaaggtgag gcaggtggcg ccagccaggt gcacacccaa      540



tgcccatgag cccagacact ggacgctgaa cctcgcggac agttaagaac ccaggggcct      600



ctgcgccctg ggcccagctc tgtcccacac cgcggtcaca tggcaccacc tctcttgcag      660



cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc acctctgggg      720



gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg acggtgtcgt      780



ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta cagtcctcag      840



gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc acccagacct      900



acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa gttggtgaga      960



ggccagcaca gggagggagg gtgtctgctg gaagccaggc tcagcgctcc tgcctggacg     1020



catcccggct atgcagcccc agtccagggc agcaaggcag gccccgtctg cctcttcacc     1080



cggaggcctc tgcccgcccc actcatgctc agggagaggg tcttctggct ttttccccag     1140



gctctgggca ggcacaggct aggtgcccct aacccaggcc ctgcacacaa aggggcaggt     1200



gctgggctca gacctgccaa gagccatatc cgggaggacc ctgcccctga cctaagccca     1260



ccccaaaggc caaactctcc actccctcag ctcggacacc ttctctcctc ccagattcca     1320



gtaactccca atcttctctc tgcagagccc aaatcttgtg acaaaactca cacatgccca     1380



ccgtgcccag gtaagccagc ccaggcctcg ccctccagct caaggcggga caggtgccct     1440



agagtagcct gcatccaggg acaggcccca gccgggtgct gacacgtcca cctccatctc     1500



ttcctcagca cctgaactcc tggggggacc gtcagtcttc ctcttccccc caaaacccaa     1560



ggacaccctc atgatctccc ggacccctga ggtcacatgc gtggtggtgg acgtgagcca     1620



cgaagaccct gaggtcaagt tcaactggta cgtggacggc gtggaggtgc ataatgccaa     1680



gacaaagccg cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt     1740



cctgcaccag gactggctga atggcaagga gtacaagtgc aaggtctcca acaaagccct     1800



cccagccccc atcgagaaaa ccatctccaa agccaaaggt gggacccgtg gggtgcgagg     1860



gccacatgga cagaggccgg ctcggcccac cctctgccct gagagtgacc gctgtaccaa     1920



cctctgtccc tacagggcag ccccgagaac cacaggtgta caccctgccc ccatcccggg     1980



atgagctgac caagaaccag gtcagcctga cctgcctggt caaaggcttc tatcccagcg     2040



acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag accacgcctc     2100



ccgtgctgga ctccgacggc tccttcttcc tctacagcaa gctcaccgtg gacaagagca     2160



ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg cacaaccact     2220



acacgcagaa gagcctctcc ctgtctccgg gtaaatgagt gcgacggccg gcaagccccc     2280



gctccccggg ctctcgcggt cgcacgagga tgcttggcac gtaccccctg tacatacttc     2340



ccgggcgccc agcatggaaa taaagcaccc agcgctgccc tgggcccctg cgagactgtg     2400



atggttcttt ccacgggtca ggccgagtct gaggcctgag tggcatgagg gaggcagagc     2460



gggtcccact gtccccacac tggcccaggc tgtgcaggtg tgcctgggcc gcctagggtg     2520



gggctcagcc aggggctgcc ctcggcaggg tgggggattt gccagcgtgg ccctccctcc     2580



agcagcacct gccctgggct gggccacggg aagccctagg agcccctggg gacagacaca     2640



cagcccctgc ctctgtagga gactgtcctg ttctgtgagc gccctgtcct ccgacctcca     2700



tgcccactcg ggggcatgcc tagtccatgt gcgtagggac aggccctccc tcacccatct     2760



acccccacgg cactaacccc tggctgccct gcccagcctc gcacccgcat ggggacacaa     2820



ccgactccgg ggacatgcac tctcgggccc tgtggaggga ctggtgcaga tgcccacaca     2880



cacactcagc ccagacccgt tcaacaaacc ccgcactgag gttggccggc cacacggcca     2940



ccacacacac acgtgcacgc ctcacacacg gagcctcacc cgggcgaact gcacagcacc     3000



cagaccagag caaggtcctc gcacacgtga acactcctcg gacacaggcc cccacgagcc     3060



ccacgcggca cctcaaggcc cacgagcctc tcggcagctt ctccacatgc tgacctgctc     3120



agacaaaccc agccctcctc tcacaagggt gcccctgcag ccgccacaca cacacagggg     3180



atcacacacc acgtcacgtc cctggccctg gcccacttcc cagtgccgcc cttccctgca     3240



ggatcc                                                                3246





<210> 4

<211> 465

<212> PRT

<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Synthetic

      polypeptide



<400> 4

Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly 

1               5                   10                  15      





Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 

            20                  25                  30          





Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 

        35                  40                  45              





Thr Asp Tyr Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 

    50                  55                  60                  





Glu Trp Ile Gly Tyr Ile Tyr Pro Tyr Asn Gly Gly Thr Gly Tyr Asn 

65                  70                  75                  80  





Gln Lys Phe Lys Ser Lys Ala Thr Ile Thr Ala Asp Glu Ser Thr Asn 

                85                  90                  95      





Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 

            100                 105                 110         





Tyr Tyr Cys Ala Arg Gly Arg Pro Ala Met Asp Tyr Trp Gly Gln Gly 

        115                 120                 125             





Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 

    130                 135                 140                 





Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 

145                 150                 155                 160 





Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 

                165                 170                 175     





Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 

            180                 185                 190         





Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 

        195                 200                 205             





Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 

    210                 215                 220                 





Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 

225                 230                 235                 240 





Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 

                245                 250                 255     





Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 

            260                 265                 270         





Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 

        275                 280                 285             





Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 

    290                 295                 300                 





Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 

305                 310                 315                 320 





Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 

                325                 330                 335     





Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 

            340                 345                 350         





Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 

        355                 360                 365             





Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 

    370                 375                 380                 





Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 

385                 390                 395                 400 





Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 

                405                 410                 415     





Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 

            420                 425                 430         





Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 

        435                 440                 445             





Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 

    450                 455                 460                 





Lys 

465 





